Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (NYSE:GSK)

37.79
Delayed Data
As of Dec 09
 +0.40 / +1.07%
Today’s Change
37.20
Today|||52-Week Range
45.58
-5.01%
Year-to-Date
Asset Sales, New Projects Fuel 6.7% Yield
Dec 07 / GuruFocus News - Paid Partner Content
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma
Dec 02 / Zacks.com - Paid Partner Content
Pfizer Takes $106 Million Fine from U.K. for Price Hike of Epilepsy Drug
Dec 07 / TheStreet.com - Paid Partner Content
Here's the Best Dividend Stock in Big Pharma
Dec 01 / MotleyFool.com - Paid Partner Content
Has GlaxoSmithKline Finally Turned the Corner?
Dec 06 / MotleyFool.com - Paid Partner Content
Merck: Keytruda's Priority Review for New Cancer Indication
Nov 29 / Zacks.com - Paid Partner Content
Robust Pipeline Supports 5.5% Dividend Yield
Dec 05 / GuruFocus News - Paid Partner Content
Glaxo (GSK) Files Regulatory Application for Shingrix in EU
Nov 28 / Zacks.com - Paid Partner Content